Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 211.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 239,595 shares of the biotechnology company’s stock after purchasing an additional 162,785 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.34% of Aclaris Therapeutics worth $594,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its position in shares of Aclaris Therapeutics by 113.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock worth $985,000 after purchasing an additional 211,585 shares during the period. Peapod Lane Capital LLC bought a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $1,003,000. Charles Schwab Investment Management Inc. bought a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $82,000. Raymond James Financial Inc. bought a new stake in Aclaris Therapeutics during the 4th quarter valued at approximately $383,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Aclaris Therapeutics by 173.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 908,819 shares of the biotechnology company’s stock valued at $2,254,000 after acquiring an additional 576,413 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Trading Up 7.4%

Shares of ACRS opened at $1.31 on Friday. The stock has a market capitalization of $141.85 million, a P/E ratio of -2.52 and a beta of 0.42. The firm’s fifty day simple moving average is $1.36 and its two-hundred day simple moving average is $2.23. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, research analysts predict that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ACRS has been the subject of a number of recent research reports. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. Scotiabank reduced their target price on Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of Aclaris Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.